Results 1 to 10 of about 6,651 (207)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes

Cells, 2022
Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin.
Natalya Maluchenko, Darya Koshkina, Anna Korovina, Vasily Studitsky, Alexey Feofanov   +4 more
doaj   +4 more sources

Mechanisms of Nucleosome Reorganization by PARP1 [PDF]

International Journal of Molecular Sciences, 2021
Poly(ADP-ribose) polymerase 1 (PARP1) is an enzyme involved in DNA repair, chromatin organization and transcription. During transcription initiation, PARP1 interacts with gene promoters where it binds to nucleosomes, replaces linker histone H1 and ...
Mikhail P. Kirpichnikov, Elena Y. Kotova, Marie-France Langelier, Natalya V. Maluchenko, Md. Sohail Akhtar, Alexey V. Feofanov, John M. Pascal, Vasily M. Studitsky, Sergey V. Pushkarev, Nadezhda S. Gerasimova, Dmitry K. Nilov   +10 more
core   +3 more sources

Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative stress-induced vascular injury

Redox Biology, 2021
Poly(ADP-ribose) polymerase 1 (PARP1) has a major regulatory role in cardiovascular disease. However, inhibiting PARP1 activity does not significantly improve clinical outcomes of cardiovascular disease, which suggests that the regulatory mechanism of ...
Liu Cao, Jingwei Liu, Yingxian Sun
exaly   +3 more sources

Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade. [PDF]

PLoS ONE, 2016
Hyperglycemia and hypertension impair endothelial function in part through oxidative stress-activated poly (ADP-ribose) polymerase 1 (PARP1). Biguanides and angiotensin II receptor blockers (ARBs) such as metformin and telmisartan have a vascular ...
Fenqing Shang, Jiao Zhang, Zhao Li, Jin Zhang, Yanjun Yin, Yaqiong Wang, Traci L Marin, Brendan Gongol, Han Xiao, You-Yi Zhang, Zhen Chen, John Y-J Shyy, Ting Lei   +12 more
doaj   +3 more sources

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models [PDF]

Molecular Cancer, 2017
Background: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action.
Annalisa Lorenzato, Napione, Lucia, Marco Basiricò, Francesca Vignolo Lutati, Giovanni Grignani, Basiricò, Marco, Chiabotto, Giulia, Pignochino, Ymera, Dell'Aglio, Carmine, Sandra Aliberti, Loretta Gammaitoni, Dario Sangiolo, Canta, Marta, Boccone, Paola, Miano, Sara, Massimo Aglietta, Erica Palesandro, Maria Serena Benassi, Gammaitoni, Loretta, Sangiolo, Dario, Aliberti, Sandra, Sara Miano, Galizia, Danilo, Palesandro, Erica, Grignani, Giovanni, Giulia Chiabotto, Lorenzato, Annalisa, Chiorino, Giovanna, Ymera Pignochino, Carmine Dell’Aglio, Paola Boccone, Lucia Napione, D'Ambrosio, Lorenzo, Federica Capozzi, Barbara Pasini, Danilo Galizia, Vignolo Lutati, Francesca, Benassi, Maria Serena, Aglietta, Massimo, Marta Canta, Capozzi, Federica, Pasini, Barbara, Giovanna Chiorino, Lorenzo D’Ambrosio   +43 more
core   +4 more sources

Nucleophagy removes cytotoxic trapped PARP1

Nature Cell Biology
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) induce cytotoxicity in homologous recombination repair (HR)-deficient (HRD) cancers by trapping PARP1 on chromatin, thereby causing irreparable replication-associated DNA damage.
Lascaux, Pauline, De Gregoriis, Giuliana, Li, Junyi, Dagg, Rebecca A., O’Brien, Darragh, Ng, Alvin Wei Tian, Rottenberg, Sven, Hou, Cynthia X., Koukouravas, Stelios, Hoslett, Gwendoline, Song, Wei, Ramadan, Kristijan, Pierangelini, Andrea, Li, Yuliang, Lord, Christopher J., Freire, Raimundo, Milosevic, Ira, Torrecilla, Ignacio, Martial, Thibaud, Krastev, Dragomir B., Raimundo, Nuno, Tarsounas, Madalena, González-Fernández, Martín, Tribble, Sara   +23 more
core   +3 more sources

THE PEPTIDOGLYCAN FRACTION ENRICHED WITH MURAMYL PENTAPEPTIDE FROM Lactobacillus bulgaricus INHIBITS GLIOBLASTOMA U373MG CELL MIGRATION CAPABILITY AND UPREGULATES PARP1 AND NF-kB LEVELS [PDF]

Biotechnologia Acta, 2020
Peptidoglycan is a universal component of bacterial walls that exerts various biological activities, including tumoricidal effect. Anti-cancer effect of various peptidoglycan fractions and their derivates is different.
V. S. Nedzvetsky, C. A. Agca, G. Baydas
doaj   +1 more source

A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells

Cell Reports
Summary: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) not only suppress PARP1 catalytic activity but also prolong its association to damaged chromatin.
Stoyno Stoynov, Irina Georgieva, Georgi Danovski   +2 more
exaly   +3 more sources

Modular synthesis of nimbolide and its analogues as PARP1 trapping inducers [PDF]

, 2022
PARP1 inhibitors (PARPi) has reshaped the clinical treatment of cancer patients with germline BRCA1/2 mutations presumably due to their ability to induce PARP1 trapping.
Heping, Deng, Hejun, Deng, Peng, Li, Tian, Qin, Chiho, Kim, Yonghao, Yu, Xudong, Wang   +6 more
core   +2 more sources

Pyridazine Based Compounds with PARP-1 Inhibitory Activity

Archives of Pharmaceutical Sciences Ain Shams University, 2023
Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman, Mai Y. Jaballah, Ahmed A. Al-Karmalawy , Khaled A. M. Abouzid   +3 more
doaj   +1 more source